What is B. Riley’s Estimate for CGTX FY2025 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at B. Riley issued their FY2025 EPS estimates for Cognition Therapeutics in a report issued on Tuesday, November 26th. B. Riley analyst M. Mamtani expects that the company will earn ($0.83) per share for the year. B. Riley has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share.

A number of other research firms also recently weighed in on CGTX. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Cognition Therapeutics in a research note on Wednesday. Chardan Capital restated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Trading Down 1.6 %

CGTX opened at $0.40 on Wednesday. The company’s 50 day moving average is $0.47 and its 200-day moving average is $1.12. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The company has a market cap of $16.53 million, a P/E ratio of -0.41 and a beta of 1.34.

Institutional Investors Weigh In On Cognition Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. CM Management LLC boosted its position in Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the period. Mercer Global Advisors Inc. ADV boosted its position in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the period. Sigma Planning Corp boosted its position in Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Virtu Financial LLC acquired a new stake in Cognition Therapeutics during the 3rd quarter worth approximately $27,000. Finally, Bangor Savings Bank raised its holdings in Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after purchasing an additional 10,000 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.